Multiple Sclerosis

---

Warwick Evidence is developing a speciality for MS-related projects and has undertaken the following multiple sclerosis appraisals:

• Ofatumumab for treating relapsing multiple sclerosis (TA699)
• Siponimod for treating secondary progressive multiple sclerosis (ID1304)
• Beta interferon and glatiramer acetate for multiple sclerosis (review of TA32) (ID809)
• Daclizumab for treating relapsing-remitting multiple sclerosis (ID827)
• Biotin for primary and secondary progressive multiple sclerosis (ID919)
• Ocrelizumab for treating primary progressive multiple sclerosis (ID938)
• Peg interferon beta 1a for multiple sclerosis (ID1521)

 

This has led to many publications and presentation at international conferences. See: Armoiry, X., et al. (2018), Chalmers J R, et al. (2014), Melendez-Torres, G. J., et al (2018a),  Melendez-Torres, G. J.et al (2017) and Miller, M. A., et al (2010)